TROPION-Breast04: Dato-DXd and durvalumab in TNBC or HR-low/HER2- breast cancer VJOncology 2:05 7 months ago 576 Скачать Далее
Efficacy of datopotamab deruxtecan, a TROP2 ADC, in aNSCLC VJOncology 1:36 3 years ago 1 230 Скачать Далее
Highlights on datopotamab deruxtecan in advanced NSCLC: The TROPION-Lung01 study European Society for Medical Oncology (ESMO) 3:09 9 months ago 2 180 Скачать Далее
BEGONIA: datopotamab deruxtecan and durvalumab in metastatic triple-negative breast cancer VJOncology 3:22 9 months ago 506 Скачать Далее
Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology Conference Total Health | Oncology 27:03 1 year ago 11 451 Скачать Далее
Phase II trial of patritumab deruxtecan in metastatic breast cancer VJOncology 3:03 1 year ago 409 Скачать Далее
DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1 VJOncology 1:08 1 year ago 159 Скачать Далее
Antibody Drug Conjugates (ADCs) Dato Potato Surviving Breast Cancer 11:40 5 months ago 83 Скачать Далее
Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer VJOncology 1:20 1 year ago 620 Скачать Далее
Dr Adwaita Gore, Datopotamab Deruxtecan Dato-DXd vs. Docetaxel in Advanced NSCLC | CRSF CRSF - Cancer Research and Statistic Foundation 7:06 1 month ago 38 Скачать Далее
TROPION-Lung01 & TROPION-Lung05: datopotamab deruxtecan for NSCLC VJOncology 1:37 2 years ago 791 Скачать Далее
TROPION-PanTumor01: datopotamab deruxtecan in advanced HER2+ breast cancer VJOncology 1:13 2 years ago 1 067 Скачать Далее
First immunotherapy success for triple-negative breast cancer QMULOfficial 1:26 5 years ago 19 920 Скачать Далее
Discover the Design Behind DXd Antibody Drug Conjugates (ADCs) Daiichi Sankyo US 2:16 9 months ago 533 Скачать Далее
Triple-negative breast cancer: a potential new treatment is now in sight Garvan Institute of Medical Research 1:59 1 year ago 14 762 Скачать Далее
